Heme/Onc Drugs Flashcards
Heparin: Mechanism
- cofactor for activation of antithrombrin
- decreased thrombrin
- decreased factor Xa
- Short half life
Heparin: Clinical Use
Immediate anticoagulation for pulmonary embolism, acute coronary syndrome, MI, DVT
- Used during pregnancy (does not cross placenta)
- Follow PTT
Heparin: Toxicity
Bleeding, thrombocytopenia (HIT), osteoporisis, drug-drug interactions.
Antidote for heparin toxicity (not to be confused with HIT)
Protamine sulfate - positively charged molecule that binds negatively charged heparin
Low molecular heparin (e.g. enoxaparin, dalteparin)
act more on factor Xa, have better bioavailability and 2-4 times longer half life
Can be administered subcutaneously and without laboratory monitoring
- Not easily reversible
Lepirudin, Bivalirudin
derivatives of hirudin (anti-coagulant used by leeches)
- inhibit thrombrin
- used as an alternative to heparin for anti-coagulating patients with HIT
Heparin-induced thrombocytopenia
development of IgG antibodies against heparin bound to platelet factor 4 (PF4).
Antibody-heparin-PF4 activates platelets –> thrombosis and thrombocytopenia
Warfarin: Mechanism
interferes with normal synthesis and gamma carboxylation of vitamin K-dependent clotting factors II, VII, IX, and X and proteins C and S.
- BLOCKS Vitamin K
- Metabolized by the cytochrome P-450 pathway
- has effect on EXTRINSIC pathway and increase in PT
- Long half-life
Warfarin: Clinical Use
Chronic anticoagulation (after STEMI, venous thromboembolism prophylaxis, and prevention of stroke in atrial fibrillation).
Follow PT/ INR values
** Don’t use in pregnncy, because unlike heparin, warfarin can cross placents
Warfarin: Toxicity
Bleeding, teratogenic, skin/tissue necrosis, drug-drug interactions
Treatment to reverse warfarin overdose
- Give vitamin K
- For rapid reversal of severe warfarin overdose, give fresh frozen plasma
Heparin
- large anionic, acidic polymer
- given parentally (IV, SC)
- acts on blood
- rapid onset
- activates thrombrin, by decreasing action of IIa (thrombrin) and factor Xa
- lasts for hours
- inhibits coagulation in vitri
- overdose treated with protamine sulfate
- monitor PTT
- doesn’t cross placenta
Warfarin
- small lipid-soluble molecule
- given orally
- acts on liver
- slow onset, limited by half lives of normal clotting factors
- impairs synthesis of vitamin K-dependent clotting factors (II, VII, IX, X, proteins C and S)
- Vitamin K antagonist
- Lasts for DAYS
- overdose treated with IV Vitamin K or fresh frozen plasma
- Monitor extrinsic pathway (PTT/INR)
- Teratogenic
Thrombolytics
Altepase (tPa), reteplase (rPA), tencteplase (TNK-tPA)
Thrombolytic: Mechanism
Directly or indirectly aid conversion of plasminogen to plasmi, which cleaves thrombin and fibrin clots.
Increases PT and PTT. NO CHANGE IN PLATELETS
Thrombolytics (“-eplase”): Clinical Use
Early MI, early ischemic stroke, direct thrombolysis of severe pulmonary embolism
Thrombolytics (“-eplase”): Toxicity
Bleeding.
Contraindicated in patients with active bleeding, history of intracranial bleeding, recent surgery, known bleeding diathesis, or severe hypertension
Tx of thrombolytic (“-eplase”) toxicity:
Aminocaproic acid - inhibitor of fibrinolysis
Aspirin: Mechanism
IRREVERSIBLY inhibits cyclooxygenase (both COX-1 and COX-2) enzyme by covalent acetylation.
Platelets cannot synthesize new enzyme, so effect lasts until new platelets are produce
- Increased bleeding time, decreased thromboxane and prostaglandins
- NO EFFECT on PT and PTT
Aspirin: Clinical Use
Antipyretic, analgesic, anti-inflammatory, antiplatelet (decreased aggregation)
Aspirin: Toxicity
Gastric ulceration, tinnitus (CN VIII).
Chronic used can lead to acute renal falire, interstitial nephritis, and upper GI bleeding
** Reye’s syndrome in children with with viral effection
Treatment of Apsitin toxicity
N-acetylation -
Aspirin toxicity is respiratory alkaltois and metabolic acidosis
ADP receptor inhibitos
Clopidogrel, Ticlipidine, Prasugrel, Ticagrelor
ADP Receptor Inhibitor: Mechanism
Inhibit platelet AGGREGATION by irreversibly binding ADP receptors. Inhibit fibrinogen binding by preventing glycoprotein IIb/IIIa from binding to fibrinogen
ADP receptor inhibitor: Clinical Use
Acute coronary syndrome
Coronary stenting
Decreased incidence or recurrence of thrombotic stroke
ADP Receptor Inhibitior: Toxicity
Neutropenia (ticlopidine)
Cliostazol, Dipyridamole: Mechanism
Phosphodiesterase III inhibitor;
Increased cAMP in platelets, thus inhibiting platelet aggregation
Vasodilators
Cliostazol, Dipyridamole: Clinical Use
Intermittent claudication, coronary vasodilation, prevention of stroke or TIAs (combined with aspirin), angina prophylaxis
Cliostazol, Dipyridamole: Toxicity
Nausea, headache, facial flushing, hypotension, abdominal pain
GP IIb/IIIa inhibitors
Abciximab, Eptifibatide, Tirofiban
GP IIb/IIIa Inhibitors (Abciximab, Eptifibatide, Tirofiban): Mechanism
Bind to the glycoprotein receptor IIb/IIa on activated platelets, preventing aggregation.
Abciximab is made from monoclonal antibody Fab fragments
GPIIb/IIIa inhibitors (Abciximab, Eptifibatide, Tirofiban): Clinical USe
Acute coronary syndromes, percutaneous transluminal coronary angioplasty
GPIIb/IIIa inhibitors (Abciximab, Eptifibatide, Tirofiban)
Bleeding, thrombocytopenia
Methotrexate (MTX): Mechanism
Folic acid analog that inhibits dihydrofolate reductase –> less dTMP –> less DNA and less protein synthesis
Methotrexate (MTX): Clinical Use
Cancers: leukemias, lymphomas, choriocarcinoma, sarcomas
Non-neoplastic: abortion, ectopic pregnancy, rheumatoid arthritis, psoriasis
Methotrexate (MTX): Toxicity
Myelosuppression, which is reversible with leucorvorin (folinic acid) “rescue”
Macrovesicular fatty chain in liver
- Mucositis
- Teratogenic
5-Fluorouracil (5-FU): Mechanism
Pyrimadine analog bioactivated to 5F-dUMP which covalently complexes folic acid.
This complex inhibits thymidylate synthase –> dTMP –> less DNA and protein synthesis
5-Fluorouracil (5-FU): Clinical Use
Colon cancer, basal cell carcinoma (topical)
5-Fluorouracil (5-FU): Toxicity
Myelosuppression, which is NOT reversible with leucorvorin
Overdose: “rescue” with thymidine
Photosensitivity
Cytarabine (arabinofuranoysl cytidine): Mechanism
Pyrimidine analog –> inhibition of DNA polymerase
Cytarabine: Clinical Use
Leukemias, lymphomas
Cytarabine: Toxicity
Leukopenia, thrombocytopenia, megaloblastic anemia